Please login to the form below

Not currently logged in

Novo Nordisk wins European approval for Refixia

Plans to launch the haemophilia B treatment in the fourth quarter

Novo Nordisk

Novo Nordisk has won EU approval for its new haemophilia drug Reflixia and is planning its first European launches in the fourth quarter.

The European Commission marketing authorisation comes one week after US regulators gave the green light to the drug, which is a long-acting Factor IX treatment for haemophilia B.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are excited about the approval of Refixia in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia B.

"The strong clinical profile of Refixia provides haemophilia B patients with better protection against bleeds, even into damaged joints, and an overall improved quality of life."

The half-life of Refixia (nonacog beta pegol or N9-GP) is around five times longer

than standard factor IX products, meaning fewer injections are needed,

Consequently Novo is hoping the new product will help defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog alfa) from Biogen and Swedish Orphan Biovitrum which was approved in the EU last year.

Article by
Dominic Tyer

7th June 2017

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...